275 Grove St., Suite 101C, Newton, MA 02466
+1 617 454 9300
2520 Meridian Parkway, Research Triangle Park, Suite 200, Durham, NC 27713
+1 919 544 3170
© 2000-2021. Parexel International Corporation.
With more than 35 years of experience guiding companies through complex GxP guidelines (good practice guidelines), we understand that breaches in compliance can impact everyone, including patients waiting for the treatments they need.
This is why we have over 80 former regulators and inspectors in our regulatory GxP compliance consulting group. These specialists working alongside our seasoned industry experts are here to help you:
We understand not only how to do this, but the importance of reducing downtime, protecting revenue, and maintaining trust with regulatory agencies.
We have your GxP compliance management details covered, so you can focus on the patients counting on you.
Learn more about how Parexel’s GxP Compliance Consulting can benefit your organization today.
How market exclusivities can affect your development program
Read Now
Case Study_Regulatory Compliance Services-NDA Approval
View Now
Case Study Achieving Product Endorsement after a FDA Warning Letter
View Now
A Harmonized Approach to Data Integrity
View Now
Case study data verification method verification and comparability
View Now
Case study data integrity assessment
View Now
Case Study data integrity warning letter
View Now
A Perspective on GMPS Cellular Therapy
View Now
Case study deviation management
View Now
Case study quality by design
View Now
How market exclusivities can affect your development program
Read Now
Case Study_Regulatory Compliance Services-NDA Approval
View Now
Case Study Achieving Product Endorsement after a FDA Warning Letter
View Now
A Harmonized Approach to Data Integrity
View Now
Case study data verification method verification and comparability
View Now
Case study data integrity assessment
View Now
Case Study data integrity warning letter
View Now
A Perspective on GMPS Cellular Therapy
View Now
Case study deviation management
View Now
Case study quality by design
View Now
Case Study Data Entry and Data Cleansing
View Now
Risk Mitigation and Compliance Consulting Brochure for BioPharma Companies
View Now
Compliance Consulting Services Brochure for Law Firms
View Now
How to interact virtually with health authorities
View Now
Parexel on the pulse
Watch Now
The Evolving Cell and Gene Therapy (CGT) Sector in China
Read Now
Five points to remember if FDA issues a Form 483
Read Now
GxP On-Site Inspections are Restarting: Preparing for inspections under the “new normal”
Read Now
FDA Expectations for Responding to Employees in Pharmaceutical Manufacturing Infected with COVID-19
Read Now
Navigating new steps in how FDA is managing COVID-19 Products
Read Now
Biosimilars in the time of COVID-19 and beyond
Read Now
Considerations for protecting your business and employees from COVID-19
Read Now
Understanding the COVID-19 regulatory procedures the FDA is using
Read Now
What Influences the Compliance Culture at FDA?
Read Now
Beware of Regional Donor Eligibility Requirements: They're Not Really the Same Everywhere!
Read Now
Demystifying FDA’s KASA Initiative… and how it aims to improve drug product, facility, and corporate quality monitoring
Read Now
As PIC/S expansion continues, what does this mean for manufacturers seeking to join?
Read Now
Restricted pharmaceutical exports from India: Are you ready to mitigate risk of drug shortages?
Read Now
Understanding Department of Justice Enforcement Policies relating to FDA-Regulated Products
Read Now
Rescuing Product Approvals from Data Integrity Issues
Read Now
FDA & Nitrosamine Impurities – The Proverb of the King with Long Arms
Read Now
Between Scylla and Charybdis – FDA Revised Draft Guidance on CGMP Compliance for 503(B) Outsourcing Facilities
Read Now
It’s Not Just Manufacturing – Drug Development Presents Corporate Compliance Risks Too
Read Now
FDA Inspections and Cleaning
Read Now
Can FDA Really Do That? Understanding FDA’s Jurisdiction
Read Now
Critical Differences Between a Form FDA 483 and Warning Letters
Read Now
Does FDA Consistently Assess Product Quality Risk and Control in Applications?
Read Now
Will FDA Withdraw an Approved Application Over Product Quality Problems?
Read Now
Don’t Shortchange Your Due Diligence When It Involves Applications – FDA Won’t
Read Now
New PIC/S recommendation for evaluating PQS effectiveness in relation to risk-based change management
Read Now
Facilities and the 356h Form - Ensuring All Relevant Manufacturing Establishments are Appropriately Identified in FDA Drug Applications
Read Now
New Post-Market Surveillance Requirements (PMS) for all Medical Device Manufacturers
Read Now
Critical CGMP Compliance Risks Go Beyond The CEO and The Park Doctrine
Read Now
Tips from FDA – Put Design of Experiments to Use in Drug Applications
Read Now
FDA Releases a Biopharmaceutical Naming Update
Read Now
Points to Consider When Mitigating Biopharmaceutical Virus Risk
Read Now
We are always available for a conversation.